Mesothelioma Nutrition and Supportive Care
| Mesothelioma Nutrition | |
|---|---|
| Appetite Loss Reported | More than 85% of patients[1] |
| Low PNI Death Risk | HR 2.29 (PNI <44.6) |
| Hypoalbuminemia 1-Year OS | 44.1% vs 72.0% |
| Recommended Energy Intake | 25-30 kcal/kg/day |
| Recommended Protein | 1.0-1.5 g/kg/day |
| B12/Folate OS (non-randomized) | 13.0 vs 8.0 months, supplemented vs not[2] |
| Mesothelioma Legal Resources | |
Executive Summary
Mesothelioma patients face a severe nutritional burden, and poorer nutritional status is associated with shorter survival. In one retrospective cohort, the prognostic nutritional index (PNI), an indicator of nutritional status, was an independent prognostic factor: patients below the cohort mean of 44.6 had a hazard ratio for death of 2.29 (95% CI 1.415-3.706; p=0.001) compared with those at or above it.[3] Serum albumin at or below 35 g/L is associated with 1-year survival of 44.1% versus 72.0% in patients with normal albumin levels, and each 1 g/L albumin increment reduces the hazard of death by 9.8%.[4]
Despite this severe nutritional burden, no dedicated mesothelioma nutrition randomized controlled trials exist as of March 2026. All clinical nutrition guidance is extrapolated from broader oncology literature, principally the ESPEN Practical Guideline on Clinical Nutrition in Cancer (2021), which recommends 25-30 kcal/kg/day total energy and 1.0-1.5 g protein/kg/day for all cancer patients.[5] Folic acid (400-1,000 mcg daily) and vitamin B12 (1 mg intramuscularly every 3 cycles) are required with pemetrexed chemotherapy.[6] In the phase III trial, adding them significantly reduced toxicity without adversely affecting survival.[7] In a separate phase II trial of single-agent pemetrexed, patients supplemented for all courses had a median overall survival of 13.0 months versus 8.0 months in those who were not, a non-randomized comparison.[2]
Emerging evidence links dietary patterns to immunotherapy outcomes, which has direct relevance given that nivolumab plus ipilimumab is one of the first-line treatment options for unresectable MPM. The PRIMM study found that higher Mediterranean diet adherence was significantly associated with immune checkpoint inhibitor response (probability of ORR 0.77; p=0.02), and a 2025 systematic review reported that high dietary fiber intake was associated with a pooled OR of 5.79 for improved immunotherapy response.[8][9] These findings underscore that nutrition management in mesothelioma extends far beyond caloric adequacy to encompass treatment efficacy and survival outcomes. Mesothelioma patients and families navigating treatment decisions may also benefit from consulting experienced mesothelioma attorneys who can help coordinate legal compensation alongside medical care.[10]
At-a-Glance
Mesothelioma nutrition and supportive care at a glance:
- Low PNI predicted shorter survival -- below the cohort mean of 44.6, hazard ratio for death 2.29 (p=0.001); median survival 11 months vs 18 months in the higher-PNI group[3]
- Hypoalbuminemia: 1-year survival 44% vs 72% -- each 1 g/L albumin increase reduces death hazard by 9.8%[4]
- Folic acid and B12 are required with pemetrexed -- their addition significantly reduced toxicity in the phase III trial[7]; in a non-randomized phase II comparison, supplemented patients had median OS of 13.0 vs 8.0 months[2]
- ESPEN recommends 25-30 kcal/kg/day and 1.0-1.5 g protein/kg/day -- the standard energy and protein targets for all cancer patients during treatment[5]
- Mediterranean diet improves immunotherapy response -- probability of overall response rate 0.77 (p=0.02) with higher adherence in ICI-treated patients[8]
- High fiber intake linked to 5.79x better ICI response -- systematic review of prospective cohorts shows dietary fiber strongly predicts immunotherapy benefit[9]
- 29.3% of CRS/HIPEC patients require parenteral nutrition -- postoperative ileus is the most common indication (63.1% of cases)[11]
- 75% of mesothelioma caregivers report personal health impacts -- nutritional distress and feeding conflicts contribute to caregiver burden including possible PTSD in up to 33%[12]
Key Facts
| Measure | Finding (Source) |
|---|---|
| Appetite Loss Prevalence | More than 85% of 495 MPM patients reported appetite loss, as well as pain, dyspnea and fatigue -- Hollen et al., 2004, PMID: 15274072[1] |
| PNI Prognostic Cutoff | PNI <44.6: HR 2.29 for death (p=0.001); 18 vs 11 months median OS -- Yao et al., 2013, PMID: 24149776[3] |
| Albumin and 1-Year Survival | 44.1% vs 72.0% (albumin <=35 vs >35 g/L) -- Yao et al., 2014, PMID: 25051913[4] |
| mGPS Prognostic Value | HR 2.6 (p<0.001) in multivariate analysis -- Pinato et al., 2012, PMID: 22307011[13] |
| ESPEN Energy Target | 25-30 kcal/kg/day total energy expenditure -- ESPEN 2021 Guideline[5] |
| ESPEN Protein Target | 1.0-1.5 g/kg/day -- ESPEN 2021 Guideline[5] |
| B12/Folate Supplementation (Phase II) | 13.0 vs 8.0 months median OS, supplemented vs non-supplemented (non-randomized) -- Scagliotti et al., 2003, PMID: 12697881[2] |
| Mediterranean Diet and ICI | ORR probability 0.77 (p=0.02) with higher adherence -- Spencer et al., JAMA Oncology 2023[8] |
| Fiber and ICI Response | OR 5.79 for improved response (prospective cohorts) -- Somodi et al., J Transl Med 2025[9] |
| Post-HIPEC PN Requirement | 29.3% of 222 CRS patients; ileus main indication (63.1%) -- PMID: 37739696[11] |
How Does Malnutrition Affect Mesothelioma Prognosis?
Malnutrition in mesothelioma is not only a quality-of-life concern: in one retrospective MPM cohort, a low prognostic nutritional index (an index of nutritional status) independently predicted shorter survival.[14] No published cohort has established how common malnutrition or sarcopenia is specifically in malignant pleural mesothelioma at diagnosis; the mesothelioma-specific evidence base consists of prognostic nutritional indices and symptom-burden data rather than prevalence figures. The inflammatory biology of asbestos-induced pleural disease and the typically advanced stage at MPM diagnosis both plausibly contribute to nutritional decline, but the magnitude has not been quantified in a published mesothelioma cohort.
Multiple compounding barriers to adequate nutrition affect mesothelioma patients. In a study of 495 patients with MPM, more than 85% reported pain, dyspnea, fatigue, and appetite loss.[1] Tumor-induced cytokine release (IL-6, TNF-alpha, IL-1beta) drives anorexia, accelerated muscle catabolism, and lipolysis. Pleural effusions in MPM cause early satiety and dyspnea during eating, while malignant ascites in peritoneal mesothelioma causes abdominal distension and nausea.
Prognostic Nutritional Index (PNI)
The PNI is calculated as: (10 x serum albumin in g/dL) + (0.005 x total lymphocyte count per mm3). A retrospective study of 121 histologically confirmed MPM patients found that PNI below 44.6 carried a hazard ratio for death of 2.290 (95% CI 1.415-3.706; p=0.001).[3] Median overall survival was 18 months for PNI-high patients versus 11 months for PNI-low patients (p=0.003), with 1-year survival rates of 72.3% versus 45.5% and 2-year survival rates of 38.7% versus 18.4%.
A second retrospective study of 132 MPM patients also found PNI below 40 to be a poor prognostic factor. A score built from PNI below 40, age 65 or older and non-epithelioid histology separated a poor prognostic group with median overall survival of 9 months from a good prognostic group with 21 months, with 1-year survival rates of 29.7% versus 77.9%.[14] A 2024 single-centre Chinese retrospective analysis of 41 patients with epithelial MPM reported that low PNI and greater summed post-chemotherapy pleural thickness were each associated with a higher risk of death; its small single-histology cohort limits how far the finding generalises.[15]
Serum Albumin
In a retrospective study of 97 MPM patients receiving platinum-based chemotherapy, 35.1% had hypoalbuminemia (albumin at or below 35 g/L) at baseline.[4] One-year overall survival was 44.1% in the hypoalbuminemic group versus 72.0% in patients with normal albumin (p<0.001). Multivariate analysis demonstrated that each 1 g/L increment in albumin reduced the hazard of death by 9.8% (HR 0.902, 95% CI 0.851-0.956; p=0.031). These findings establish serum albumin as a practical, widely available prognostic marker that should be routinely monitored in mesothelioma patients. Understanding prognosis factors can help patients and families make informed treatment and legal decisions.[16]
Modified Glasgow Prognostic Score (mGPS)
The mGPS captures systemic inflammatory burden through two serum markers: C-reactive protein (CRP) and albumin. In the scoring used by Pinato and colleagues, patients with both a normal albumin (above 35 g/L) and a normal CRP (below 10 mg/L) score 0, patients with one of these abnormalities score 1, and patients with both abnormal score 2.[13]
In a validation study of inflammation-based indices in MPM, multivariate analysis confirmed mGPS (HR 2.6; p<0.001) and neutrophil-to-lymphocyte ratio (HR 2.0; p=0.008) as independent predictors of overall survival, outperforming the European EORTC Prognostic Score.[13] A larger multicenter analysis identified the CRP/albumin ratio (CAR) as a strong independent prognostic factor, with epithelioid histology patients having low CAR achieving overall survival of 32.0 months versus 11.0 months (p<0.001).[17] The Mesothelioma Systemic Inflammation Score (MSIS), a 2025 composite score developed in 195 patients and validated in an independent cohort of 80, demonstrated independent prognostic value for overall survival and predictive value for benefit from multimodality treatment.[18]
What Are the Evidence-Based Nutrition Guidelines for Mesothelioma?
ESPEN Practical Guideline on Clinical Nutrition in Cancer (2021)
No mesothelioma-specific nutrition guideline exists; the ESPEN Practical Guideline covers patients with cancer generally.[5] Key recommendations include:
| Recommendation | Strength | Detail |
|---|---|---|
| Screen all cancer patients at diagnosis | Strong | Regularly evaluate intake, weight change and BMI, beginning with diagnosis |
| Total energy: 25-30 kcal/kg/day | Strong | Applies when energy expenditure is not measured individually |
| Protein: 1.0-1.5 g/kg/day | Strong | Above 1 g/kg/day and, if possible, up to 1.5 g/kg/day |
| Vitamins/minerals at RDA levels | Strong | No high-dose supplementation unless deficiency documented |
| Omega-3/fish oil for weight-losing patients | Weak | Long-chain n-3 fatty acids or fish oil in advanced cancer on chemotherapy |
| ERAS protocols for surgical patients | Strong | For curative or palliative surgery |
| No routine ANH in actively dying patients | Strong (consensus) | Treatment based on comfort |
ESPEN's 1.0-1.5 g/kg/day protein recommendation is directed at cancer patients generally and is not mesothelioma-specific; no mesothelioma-specific protein target has been established in a published cohort.[5]
Pemetrexed Mandatory Vitamin Supplementation
Folic acid and vitamin B12 supplementation is a mandatory pharmaceutical protocol requirement for all patients receiving pemetrexed, the cornerstone of mesothelioma chemotherapy.[7] The pivotal Phase III randomized controlled trial assigned 456 MPM patients to pemetrexed plus cisplatin or cisplatin alone; folic acid and vitamin B12 were added after 117 patients had enrolled, and their addition significantly reduced toxicity without adversely affecting survival. Across all patients, median overall survival was 12.1 months with pemetrexed plus cisplatin versus 9.3 months with cisplatin alone (HR 0.77; p=0.020), a treatment effect rather than a supplementation effect.[7] In a Phase II single-agent pemetrexed trial, the 43 patients supplemented for all courses had a median OS of 13.0 months versus 8.0 months in the 21 who were not; the comparison was not randomized, and the authors concluded that patients "could benefit" from pemetrexed combined with vitamin supplementation.[2]
The prescribing information calls for folic acid 400-1,000 mcg orally once daily, starting 7 days before the first pemetrexed dose and continuing until 21 days after the last dose, plus vitamin B12 1 mg intramuscularly 1 week before the first dose and every 3 cycles.[6] In a single-center retrospective study of 281 patients, same-day vitamin B12 showed no significant difference in hematologic changes, although treatment delay at cycle 3 was more frequent with same-day dosing (24.6% vs 11.9%).[19]
What Should Mesothelioma Patients Eat During Chemotherapy?
Anti-Inflammatory Dietary Patterns
The Mediterranean diet is the best-studied anti-inflammatory dietary pattern in oncology with direct relevance to mesothelioma patients receiving immunotherapy. The PRIMM study of 91 advanced melanoma patients on immune checkpoint inhibitors found that higher adherence to Mediterranean dietary principles was significantly associated with probability of response (probability of ORR 0.77; p=0.02), driven by whole grains, fish, nuts, fruit, vegetables, and legumes.[8]
Because nivolumab plus ipilimumab is one of the first-line treatment options for unresectable MPM, this dietary-immunotherapy relationship has direct clinical relevance. A 2025 systematic review found that high versus low dietary fiber intake was associated with a pooled OR of 5.79 for improved ICI response in prospective cohort studies.[9] A 2025 clinical intervention study of 132 cancer survivors showed significant post-intervention reduction in IL-1beta, IL-6, IL-8, and TNF-alpha with Mediterranean diet adherence, confirming anti-inflammatory mechanisms.[20]
Managing Chemotherapy Side Effects Through Diet
| Side Effect | Dietary Strategy | Evidence Basis |
|---|---|---|
| Nausea/vomiting | Bland, soft, easy-to-digest foods rather than heavy meals; dry foods such as crackers or toast through the day | NCI Nutrition in Cancer Care (PDQ)[21] |
| Mucositis | Baking soda and salt mouth rinse 3 to 4 times a day; avoid mouthwash containing alcohol; no tobacco | NCI Nutrition in Cancer Care (PDQ)[21] |
| Dysgeusia (metallic taste) | Plastic utensils; do not drink from metal containers; marinate foods, or eat meat with something sweet | NCI Nutrition in Cancer Care (PDQ)[21] |
| Appetite loss | Small, frequent meals and healthy snacks; foods high in protein and calories, with high-protein foods first while appetite is strongest | NCI Nutrition in Cancer Care (PDQ)[21] |
| Fatigue affecting cooking | Pre-prepared nutrient-dense meals; assistance from caregivers; ready-to-drink oral nutritional supplements | Help-Meso qualitative interviews; ESPEN 2021 ONS guidance[22][5] |
Hydration During Cisplatin Treatment
Adequate hydration is a renal cytoprotection strategy essential during cisplatin-based chemotherapy. In a single-centre series of 84 patients receiving hyperthermic intrathoracic chemotherapy with intrapleural cisplatin, 34.5% developed renal insufficiency; those given perioperative cytoprotection alongside fluid balancing had significantly lower post-operative creatinine despite higher cisplatin doses.[23] Pre- and post-infusion fluid protocols for systemic cisplatin are set by the treating centre and vary by regimen, so patients should follow the specific hydration instructions given by their own oncology team.
Cisplatin can cause hypomagnesemia, hypocalcemia, hyponatremia, hypokalemia, and hypophosphatemia; the drug label attributes these probably to renal tubular damage.[24] The label notes that normal serum electrolyte levels are generally restored by supplemental electrolytes and discontinuing cisplatin.[24]
Oral Nutritional Supplements
For patients who are malnourished or at risk of malnutrition, ESPEN recommends nutritional intervention that includes dietary advice, treatment of symptoms that impair food intake, and offering oral nutritional supplements (ONS); if oral nutrition remains inadequate despite counseling and ONS, it recommends enteral nutrition, and parenteral nutrition if enteral nutrition is not sufficient or feasible.[5]
Which Supplements Are Safe During Mesothelioma Treatment?
Mandatory Supplements: Folic Acid and Vitamin B12
As detailed above, folic acid (400-1,000 mcg daily) and vitamin B12 (1 mg IM every 3 cycles) are required for all patients receiving pemetrexed.[6] In the phase III trial their addition significantly reduced toxicity without adversely affecting survival.[7]
Omega-3 Fatty Acids
EPA and DHA modulate pro-inflammatory cytokines (IL-6, TNF-alpha) that drive cachexia. A prospective randomized controlled trial in gastrointestinal cancer patients found that fish oil prevented increases in serum CRP and significantly increased skeletal muscle mass and lean body mass compared to controls, with specific benefit in patients with mGPS scores of 1 or 2.[25] ESPEN 2021 makes a weak recommendation for long-chain n-3 fatty acids or fish oil in patients with advanced cancer undergoing chemotherapy who are at risk of weight loss or malnourished.[5] No mesothelioma-specific omega-3 evidence exists; all data is extrapolated from pancreatic, gastrointestinal, and general advanced cancer populations. Omega-3s may reduce platelet aggregation and should be discontinued 5-7 days before surgery.[25]
Glutamine for Mucositis
Pemetrexed-based chemotherapy can cause oral and gastrointestinal mucositis. The evidence for glutamine comes from mixed-cancer and head-and-neck populations, not from mesothelioma trials. A meta-analysis of 15 RCTs with 988 participants with cancer found that glutamine reduced mucositis severity (SMD -0.73), reduced incidence of severe mucositis (RR 0.41), reduced opioid analgesic use (RR 0.84), feeding tube use (RR 0.46), hospitalization (RR 0.39), and treatment interruption (RR 0.49).[26] A controlled trial in patients with locally advanced head and neck cancer receiving chemoradiotherapy found glutamine significantly decreased mean maximal mucositis grade (2.9 vs 3.3; p=0.005).[27] No mesothelioma-specific trial of glutamine for mucositis has been published.
Vitamin D
Vitamin D deficiency is common in cancer patients. The only mesothelioma-specific pre-clinical vitamin D data comes from a mouse model study that found vitamin D supplementation did not reduce mesothelioma incidence or severity in asbestos-exposed mice.[28] The VITAL trial (25,871 participants, 2000 IU/day vitamin D) found no lower incidence of invasive cancer; the hazard ratio for death from cancer was 0.83 (95% CI, 0.67 to 1.02).[29] ESPEN recommends vitamins and minerals at about the recommended daily allowance and discourages high-dose micronutrients in the absence of a specific deficiency.[5]
Supplements to Avoid During Treatment
| Supplement | Interaction Risk | Recommendation |
|---|---|---|
| High-dose vitamin C | ESPEN discourages high-dose micronutrients in the absence of a specific deficiency | Keep to recommended daily amounts unless a deficiency is documented[5] |
| High-dose vitamin E | ESPEN discourages high-dose micronutrients in the absence of a specific deficiency | Keep to recommended daily amounts unless a deficiency is documented[5] |
| Beta-carotene | Increased lung cancer incidence in male smokers (ATBC) and, given with vitamin A, in smokers and asbestos-exposed workers (CARET)[30][31] | Avoid high-dose supplements in the absence of a specific deficiency[5] |
| St. John's Wort | Induces the drug-metabolizing enzyme CYP3A4; numerous documented interactions with conventional drugs | Avoid during chemotherapy[32] |
| Garlic supplements | May increase the risk of bleeding or bruising, including with warfarin or other blood thinners | Stop 1–2 weeks before surgery[33] |
| Asian ginseng (Panax ginseng) | Do not exceed recommended doses; avoid non-standardized products, especially with anticoagulants or some CYP450 substrates | Stop at least 1 week before surgery[34] |
ESPEN recommends vitamins and minerals in amounts approximately equal to the recommended daily allowance and discourages high-dose micronutrients in the absence of specific deficiencies.[5] Patients weighing complementary or integrative options alongside conventional care can review patient-facing resources such as the Annie Appleseed Project's directory of complementary and alternative cancer therapies to help inform those discussions with their oncology team.[35]
What Are the Nutritional Needs for Peritoneal Mesothelioma Patients?
Diffuse malignant peritoneal mesothelioma (DMPM) represents 5% to 30% of malignant mesothelioma cases in published estimates.[36] One review puts it at 10–15% of all mesotheliomas.[37]
Disease-Specific Challenges
Malignant ascites complicates nutritional assessment: body weight may reflect fluid shifts, edema or ascites rather than actual changes in fat and lean body mass.[21]
Bowel involvement can limit how much nutrition the gut can take in. ESPEN's cancer guideline states that in severe intestinal insufficiency due to causes including chronic bowel obstruction or peritoneal carcinosis, nutritional status can be maintained by parenteral nutrition.[5]
CRS/HIPEC Nutritional Management
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the primary curative therapy for peritoneal mesothelioma in selected patients.[36] In a multi-institutional registry of 405 DMPM patients, median overall survival was 53 months; 31% had grade 3 to 4 complications and 2% died perioperatively.[38]
A 2024 retrospective analysis of 140 patients undergoing cytoreductive surgery with or without HIPEC found that preoperative nutritional status was significantly associated with postoperative outcomes: patients requiring parenteral nutrition had significantly longer post-operative, hospital, and ICU length of stay (p=0.001).[39] In a separate series of 60 patients undergoing CRS and HIPEC, preoperative Subjective Global Assessment predicted both length of stay (15.0, 15.2 and 27.8 days across well-nourished, mildly-moderately malnourished and severely malnourished groups; p=0.02) and median survival (22.4 versus 10.4 months; p=0.006).[40]
| Phase | Nutritional Challenge | Recommended Strategy |
|---|---|---|
| Pre-operative | Malnutrition | Screen for nutritional risk and treat it before surgery; avoid prolonged preoperative fasting. No mesothelioma-specific duration or protein target is established[41] |
| Early post-op (Days 0-3) | Post-HIPEC ileus, stress response | Early enteral nutrition preferred if feasible[39] |
| Later post-op (Days 3-14) | Partial ileus, pain, poor appetite | ONS if oral intake remains inadequate[5] |
| Post-discharge chemotherapy | Systemic chemotherapy side effects | Standard pemetrexed protocol with mandatory folic acid and B12[7] |
A retrospective analysis of 321 patients at a single UK national referral centre found that most CRS/HIPEC patients required parenteral nutrition for more than 7 days, with poor pre-operative nutritional status and inability to achieve complete cytoreduction as predictors of prolonged PN requirement, and a median PN duration of 9 days (range 2-87 days).[42] Among 222 CRS patients at Peter MacCallum Cancer Centre, 29.3% required postoperative PN, with postoperative ileus as the most frequent indication (63.1% of PN cases).[11]
Peritoneal mesothelioma patients undergoing CRS/HIPEC should receive pre-operative nutritional assessment and optimization as part of their multidisciplinary care plan.[43]
How Should Nutrition Be Managed in Palliative Mesothelioma Care?
ESPEN's guidance differs by phase of illness, from anticancer treatment to advanced disease without anticancer treatment and the dying phase.[5]
Active Treatment Phase
During anticancer drug treatment, ESPEN recommends ensuring an adequate nutritional intake and maintaining physical activity. Targets include 25-30 kcal/kg/day energy and 1.0-1.5 g protein/kg/day.[5]
Palliative Phase
For patients with advanced cancer, ESPEN recommends offering nutritional interventions only after weighing, together with the patient, the prognosis, the expected benefit on quality of life and survival, and the burden of nutritional care.[5]
Terminal Phase
ESPEN 2021 recommends that in dying patients treatment be based on comfort; parenteral hydration and nutrition are unlikely to provide any benefit for most patients.[5] Terminal cancer anorexia is a cytokine-driven state that cannot be reversed by increasing caloric input alone. Artificial nutrition and hydration (ANH) at end of life does not significantly improve survival or quality of life in terminal cancer patients.[44]
In acute confusional states, ESPEN suggests a short and limited course of hydration to rule out dehydration as a precipitating cause.[5]
Family and Caregiver Guidance
Families often experience profound distress when their loved one refuses food. A 2024 mesothelioma-specific systematic review confirmed that 75% of mesothelioma caregivers report personal health impacts and up to 33% develop possible PTSD.[12] Nutritional distress and conflict over feeding are embedded in this broader caregiver burden.
Key messages for families include: inadequate calorie intake in terminal cancer reflects the dying process and not a failure of caregiving; pressure to eat increases patient anxiety, nausea, and discomfort without providing survival benefit; small amounts of preferred foods provide sensory pleasure and emotional connection without imposing clinical goals; and artificial nutrition should not be equated with giving up. Mesothelioma support resources are available for patients and families navigating these difficult decisions.[45]
What Clinical Studies Support Nutritional Interventions in Mesothelioma?
| Study | Year / N | Key Finding |
|---|---|---|
| Help-Meso (Taylor et al.; Dismore et al.) | 2022 protocol; 2024 results / n=23 | Protocol reports no outcome data; the only published results are qualitative -- 23 participants, 12 of them people living with mesothelioma -- and report no prevalence figures[46][22] |
| PNI in MPM (Yao et al.) | 2013 / n=121 | PNI <44.6: HR 2.29 for death (p=0.001); 18 vs 11 months OS[3] |
| Albumin in MPM (Yao et al.) | 2014 / n=97 | Hypoalbuminemia HR 1.778; 44.1% vs 72.0% 1-year OS[4] |
| mGPS/NLR in MPM (Pinato et al.) | 2012 / Retrospective | mGPS HR 2.6 (p<0.001); NLR HR 2.0 (p=0.008)[13] |
| PNI in 132 MPM (Cakir et al.) | 2022 / n=132 | PNI ≤40 vs >40: 12 vs 21 months median OS[14] |
| CAR in MPM (Multicenter) | 2025 / Multicenter | Epithelioid with low CAR: OS 32.0 vs 11.0 months (p<0.001)[17] |
| MSIS Score Validation | 2025 / 195 patients + 80 validation | Independent prognostic and predictive value for multimodality benefit[18] |
| Pemetrexed Phase III (Vogelzang) | 2003 / n=456 | Pemetrexed + cisplatin vs cisplatin: 12.1 vs 9.3 months OS (HR 0.77; p=0.020)[7] |
| Pemetrexed Phase II (Scagliotti) | 2003 / Phase II | Supplemented vs non-supplemented (non-randomized): 13.0 vs 8.0 months OS[2] |
| Fish oil and chemotherapy (Fujimoto) | 2017 / RCT | Prevented CRP rise; increased muscle mass in mGPS 1/2 patients[25] |
| Glutamine meta-analysis (Tang) | 2022 / 15 RCTs, 988 | Reduced severe mucositis (RR 0.41), hospitalization (RR 0.39) — mixed-cancer meta-analysis, not mesothelioma-specific[26] |
| Post-HIPEC PN (222 CRS patients) | 2023 / n=222 | 29.3% required post-op PN; ileus main indication (63.1%)[11] |
No registered Phase II or III RCTs exist that study nutrition interventions specifically and exclusively in mesothelioma patients as of March 2026. Help-Meso is the most mesothelioma-specific nutritional research programme, but its 2022 publication is a study protocol that reports no outcome data, and its only published results to date are qualitative interviews with 23 participants, 12 of them people living with mesothelioma.[46][22]
Frequently Asked Questions
What is the best diet for mesothelioma patients?
There is no single best diet for mesothelioma patients, but the ESPEN 2021 guidelines recommend 25-30 kcal/kg/day total energy and 1.0-1.5 g protein/kg/day for all cancer patients during treatment.[5] A Mediterranean-style dietary pattern emphasizing whole grains, fish, nuts, fruits, vegetables, and legumes has shown significant association with improved immunotherapy response and anti-inflammatory effects. Patients should work with an oncology dietitian to create an individualized nutrition plan that accounts for their specific treatment regimen, symptoms, and nutritional status.
Are folic acid and vitamin B12 required during mesothelioma chemotherapy?
Yes. Folic acid (400-1,000 mcg orally once daily) and vitamin B12 (1 mg IM every 3 cycles) are required for all patients receiving pemetrexed.[6] These supplements are not optional; in the phase III trial, adding them significantly reduced toxicity without adversely affecting survival.[7] Folic acid starts 7 days before the first pemetrexed dose and continues until 21 days after the last dose.[6]
Should mesothelioma patients take antioxidant supplements?
ESPEN recommends that vitamins and minerals be supplied in amounts approximately equal to the recommended daily allowance, and discourages high-dose micronutrients in the absence of specific deficiencies.[5] In two large trials, beta-carotene supplements increased lung cancer incidence: in male smokers (ATBC), and, combined with vitamin A, in smokers and asbestos-exposed workers (CARET).[30][31] Discuss any supplement beyond these levels with the oncology team.
How does malnutrition affect mesothelioma survival?
In one retrospective cohort, a low prognostic nutritional index (PNI, an index of nutritional status) independently predicted shorter survival: patients below the cohort mean of 44.6 had a hazard ratio for death of 2.29 (p=0.001), with median survival of 11 months versus 18 months in the higher-PNI group.[3] Hypoalbuminemia (albumin at or below 35 g/L) is associated with 1-year survival of just 44.1% versus 72.0% in patients with normal albumin.[4] Nutritional screening at diagnosis and throughout treatment is essential.
What should peritoneal mesothelioma patients eat before HIPEC surgery?
Peritoneal mesothelioma patients preparing for CRS/HIPEC should be assessed and nutritionally optimised before surgery. ESPEN's surgical guideline is the applicable framework: it calls for integrating nutrition into overall management, avoiding long periods of preoperative fasting, starting nutritional therapy as soon as nutritional risk becomes apparent, and re-establishing oral feeding as early as possible after surgery.[41] Neither that guideline nor the ESPEN cancer guideline sets a mesothelioma-specific prehabilitation duration or preoperative protein target, and no published cohort has established one. Poorer preoperative nutritional status is associated with longer hospital stay and shorter survival after CRS/HIPEC.[40] Patients should work closely with a surgical team and dietitian at a specialized mesothelioma treatment center.[47]
When should artificial nutrition be stopped in terminal mesothelioma?
ESPEN 2021 recommends that in dying patients treatment be based on comfort; parenteral hydration and nutrition are unlikely to provide any benefit for most patients.[5] Artificial nutrition and hydration at end of life does not significantly improve survival or quality of life in terminal cancer patients.[44] The focus should shift to comfort, dignity, and small amounts of preferred foods for sensory pleasure. Palliative care teams should proactively discuss nutrition expectations with families.
Does diet affect immunotherapy response in mesothelioma?
Emerging evidence suggests dietary patterns may be associated with immunotherapy outcomes. The PRIMM study found that Mediterranean diet adherence was associated with a probability of ORR 0.77 (p=0.02) in patients receiving immune checkpoint inhibitors, and a 2025 systematic review reported that high fiber intake was associated with an OR of 5.79 for improved ICI response.[8][9] Because nivolumab plus ipilimumab is one of the first-line treatment options for unresectable mesothelioma, these dietary-immunotherapy findings have direct clinical relevance, though mesothelioma-specific microbiome data is not yet available.
Quick Statistics
- More than 85% report pain, dyspnea, fatigue and appetite loss[1]
- PNI <44.6 carries HR 2.29 for death (p=0.001)[3]
- Hypoalbuminemia associated with 44.1% vs 72.0% 1-year survival[4]
- mGPS independently predicts survival with HR 2.6 (p<0.001)[13]
- 25-30 kcal/kg/day recommended energy intake (ESPEN 2021)[5]
- 1.0-1.5 g/kg/day recommended protein intake for cancer patients[5]
- B12/folate supplementation is required with pemetrexed and significantly reduced toxicity in the phase III trial[7]
- Mediterranean diet associated with ORR probability 0.77 (p=0.02) with immunotherapy[8]
- High fiber intake OR 5.79 for improved ICI response[9]
- 29.3% of CRS/HIPEC patients require post-operative parenteral nutrition[11]
- 75% of mesothelioma caregivers report personal health impacts[12]
- Glutamine reduces severe mucositis (RR 0.41) and hospitalization (RR 0.39) in mixed-cancer populations; no mesothelioma trial has tested it[26]
External Links
- Danziger & De Llano -- Mesothelioma legal representation and patient resources.
- Mesothelioma Lawyers Near Me -- Comprehensive resources on mesothelioma treatment, legal options, and patient support.
- Mesothelioma.net -- Treatment information and patient resources.
Related Pages
- Understanding Your Mesothelioma Diagnosis
- Mesothelioma Clinical Trials
- Mesothelioma Treatment Centers
- Mesothelioma Survival Statistics
- Mesothelioma Quick Facts
References
- ↑ 1.0 1.1 1.2 1.3 Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation. Cancer. 2004;101(3):587-595. PMID: 15274072 PubMed.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21(8):1556-1561. PMID: 12697881 PubMed.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Yao ZH, Tian GY, Wan YY, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2013;139(12):2117-2123. PMID: 24149776 PubMed.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Yao ZH, Tian GY, Yang SX, et al. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma. Tumour Biol. 2014;35(7):6839-6845. PMID: 25051913 PubMed.
- ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 5.20 5.21 5.22 5.23 5.24 5.25 Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021;40(5):2898-2913. PMID: 33946039 PubMed. doi:10.1016/j.clnu.2021.02.005
- ↑ 6.0 6.1 6.2 6.3 6.4 Pemetrexed for injection: prescribing information. DailyMed, U.S. National Library of Medicine.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. PMID: 12860938 PubMed.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 Spencer CN, et al. (2023). Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. JAMA Oncology. doi:10.1001/jamaoncol.2023.1181
- ↑ 9.0 9.1 9.2 9.3 9.4 9.5 Somodi L, et al. (2025). Dietary fiber intake and immune checkpoint inhibitor response: a systematic review. Journal of Translational Medicine. doi:10.1186/s12967-025-06586-0
- ↑ Danziger & De Llano -- Mesothelioma Legal Representation.
- ↑ 11.0 11.1 11.2 11.3 11.4 Khan A, Beaumont A, Laing E, et al. Parenteral nutrition after cytoreductive surgery for peritoneal malignancy: Should it be administered routinely?. Clin Nutr ESPEN. 2023;57:487-493. PMID: 37739696 PubMed.
- ↑ 12.0 12.1 12.2 Tod E, et al. (2024). Patient and caregiver experience of mesothelioma: a systematic review. BMJ Open. doi:10.1136/bmjopen-2023-075071
- ↑ 13.0 13.1 13.2 13.3 13.4 Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7(3):587-594. PMID: 22307011 PubMed.
- ↑ 14.0 14.1 14.2 Ebinç S, Oruç Z, Kalkan Z, Karhan O, Urakçı Z, Küçüköner M, Kaplan MA, Abdurrahman I. Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. Turk Gogus Kalp Damar Cerrahisi Derg. 2023;31(1):105-115. Retrospective, n=132. PMID: 36926157 PubMed. doi:10.5606/tgkdc.dergisi.2023.23365
- ↑ Zhou JH, Zhang YL, Li LF, Lu PL. Correlation between prognostic nutritional index and pleural thickness with survival time of epithelial malignant pleural mesothelioma patients. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2024;42(2):118-123. Article in Chinese with English abstract; retrospective, single centre, n=41 epithelial MPM. PMID: 38403420 PubMed
- ↑ Mesothelioma Overview. Mesothelioma Lawyer Center.
- ↑ 17.0 17.1 Sever N, Yildirim S, Gurbuz AF, et al. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis. Medicina. 2025;61(1):144. doi:10.3390/medicina61010144
- ↑ 18.0 18.1 Mosleh B, Sinn K, Cho A, Reiner A, Steindl A, Lang C, et al. The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma. Cancers. 2025;17(8):1371. doi:10.3390/cancers17081371
- ↑ Schlei Z, Tan W, Faber MG, et al. Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis. Clin Lung Cancer. 2018;19(6):467-475. PMID: 30369425 PubMed.
- ↑ Di Tolla MF, Libutti M, D'Onofrio G, Riccio A, Cabaro S, Longo M, et al. Unraveling the anti-inflammatory effects of Mediterranean diet in patients with cancer remission. Front Immunol. 2025;16:1666611. doi:10.3389/fimmu.2025.1666611
- ↑ 21.0 21.1 21.2 21.3 21.4 PDQ Supportive and Palliative Care Editorial Board. Nutrition in Cancer Care (PDQ®)–Health Professional Version. National Cancer Institute.
- ↑ 22.0 22.1 22.2 Dismore LL, Taylor LL, Aujayeb A, Hurst C, Swainston K. Patients with mesothelioma and their carer's experience of diet and appetite: A qualitative insight from the Help-Meso Study. J Hum Nutr Diet. 2024;37(3):717-725. Qualitative; 23 participants, 12 of them people living with mesothelioma; thematic analysis. PMID: 38583133 PubMed. doi:10.1111/jhn.13301
- ↑ Markowiak T, Kerner N, Neu R, Potzger T, Großer C, Zeman F, Hofmann HS, Ried M. Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy. J Surg Oncol. 2019;120(7):1220-1226. Single centre, n=84. PMID: 31602673 PubMed. doi:10.1002/jso.25726
- ↑ 24.0 24.1 Cisplatin injection: prescribing information. DailyMed, U.S. National Library of Medicine.
- ↑ 25.0 25.1 25.2 Fujimoto A, et al. (2017). Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Scientific Reports, 7:4826. doi:10.1038/s41598-017-05278-0
- ↑ 26.0 26.1 26.2 Tang G, Huang W, Zhang L, et al. Role of Glutamine in the Management of Oral Mucositis in Patients with Cancer: A Meta-Analysis of Randomized Controlled Trials. Nutr Cancer. 2022;74(2):482-495. PMID: 33605813 PubMed.
- ↑ Tsujimoto T, Yamamoto Y, Wasa M, et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep. 2015;33(1):33-39. PMID: 25351453 PubMed.
- ↑ Robinson C, Woo S, Nowak AK, et al. Dietary vitamin D supplementation does not reduce the incidence or severity of asbestos-induced mesothelioma in a mouse model. Nutr Cancer. 2014;66(3):383-387. PMID: 24564337 PubMed.
- ↑ Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44. PMID: 30415629 PubMed. doi:10.1056/NEJMoa1809944
- ↑ 30.0 30.1 Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029-35. PMID: 8127329 PubMed. doi:10.1056/NEJM199404143301501
- ↑ 31.0 31.1 Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150-5. PMID: 8602180 PubMed. doi:10.1056/NEJM199605023341802
- ↑ St. John's Wort. About Herbs, Memorial Sloan Kettering Cancer Center.
- ↑ Garlic. About Herbs, Memorial Sloan Kettering Cancer Center.
- ↑ Ginseng (Asian). About Herbs, Memorial Sloan Kettering Cancer Center.
- ↑ Complementary and Alternative Cancer Therapy Resources. Annie Appleseed Project.
- ↑ 36.0 36.1 Steadman JA, Grotz TE. Principles of Surgical Management of Peritoneal Mesothelioma. J Natl Compr Canc Netw. 2023;21(9):981-986. PMID: 37673112 PubMed. doi:10.6004/jnccn.2023.7055
- ↑ Levý M, Boublíková L, Büchler T, Šimša J. Treatment of Malignant Peritoneal Mesothelioma. Klin Onkol. 2019;32(5):333-337. PMID: 31610664 PubMed. doi:10.14735/amko2019333
- ↑ Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42. PMID: 19917862 PubMed. doi:10.1200/JCO.2009.23.9640
- ↑ 39.0 39.1 AlTawil E, Kalagi NA, Alzahrani S, Alobeed F, Alshammari S, Bin Traiki T. The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing cytoreductive surgery: a retrospective study. Front Nutr. 2024;11:1364959. Retrospective, n=140 (40 on parenteral nutrition, 100 not). PMID: 38765813 PubMed. doi:10.3389/fnut.2024.1364959
- ↑ 40.0 40.1 Vashi PG, Gupta D, Lammersfeld CA, Braun DP, Popiel B, Misra S, Brown KC. The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. Nutr J. 2013;12:118. Retrospective, n=60. PMID: 23941331 PubMed. doi:10.1186/1475-2891-12-118
- ↑ 41.0 41.1 Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN practical guideline: Clinical nutrition in surgery. Clin Nutr. 2021;40(7):4745-4761. PMID: 34242915 PubMed. doi:10.1016/j.clnu.2021.03.031
- ↑ Swain DR, Yates AL, Mohamed F, Dayal SP, Tzivanakis A, Cecil TD, Moran BJ. Do patients undergoing cytoreductive surgery and HIPEC for peritoneal malignancy need parenteral nutrition?. Pleura Peritoneum. 2018;3(4):20180123. Retrospective, n=321, single UK national referral centre. PMID: 30911667 PubMed. doi:10.1515/pp-2018-0123
- ↑ Peritoneal Mesothelioma Cancer. Mesothelioma Lawyer Center.
- ↑ 44.0 44.1 Ganzini L (2006). Artificial nutrition and hydration at the end of life: ethics and evidence. Palliative and Supportive Care, 4(2):135-143. doi:10.1017/S1478951506060196
- ↑ Mesothelioma Diagnosis Guide. Danziger & De Llano.
- ↑ 46.0 46.1 Taylor L, Swainston K, Hurst C, Aujayeb A, Poulter H, Dismore L. Health and Lifestyle of Patients with Mesothelioma: Protocol for the Help-Meso Study. J Respir. 2022;2(3):129-138. Study protocol; reports no outcome data. doi:10.3390/jor2030011
- ↑ Mesothelioma Treatment Centers. Mesothelioma.net.